NCT04523857View on ClinicalTrials.gov

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

November 1, 2021

Primary Completion Date

December 31, 2027

Study Completion Date

December 31, 2028

Conditions
Breast Cancer
Interventions
DRUG

Abemaciclib

Oral CDK4/6 inhibitor to target bone marrow disseminated tumor cells (DTCs)

DRUG

Hydroxychloroquine

Oral autophagy inhibitor to target bone marrow disseminated tumor cells (DTCs)

Trial Locations (1)

19104

RECRUITING

Abramson Cancer Center of the University of Pennsylvania, Philadelphia

All Listed Sponsors
lead

Abramson Cancer Center at Penn Medicine

OTHER